A.V. BORODIN

Moscow Regional Research and Scientific Clinical Institute named after M.F Vladimirsky, 61/2 Schepkin Stt., buld. 10, Moscow, Russian Federation, 129110

 Borodin A.V. ― Neurologist of the Department of Neurology, e-mail: borodinonav@yandex.ru, ORCID ID: 000-0002-8439-7783

 Objective ― to analyze the available domestic and foreign literature on the use of transimmunization and photopheresis in the treatment of autoimmune diseases in neurology.

Results. Extracorporeal photochemotherapy (ECP) or photopheresis is a method of ultraviolet (UV) irradiation of peripheral blood mononuclear cells outside the body. To increase the sensitivity of blood cells to UV irradiation, 8-methoxypsoralen is used. The technique was first published by Edelson R.L in 1984 and was used to treat lymphoma. The review presents data on application of the technique in various fields of medicine, including neurology for the treatment of myasthenia and multiple sclerosis. Multiple sclerosis is an autoimmune disease of the central nervous system characterized by inflammation and demyelination, leading to the loss of axons, in the pathogenesis of which the role of T-lymphocytes is established. Currently, there are a lot of drugs which cause an immunomodulatory effect. However, treatment is not always effective. Such side effects as intolerance, formation of antibodies to these drugs, are possible. Therefore, the search for new methods of treatment is relevant. The mechanism of action of UV irradiation of lymphocytes of peripheral blood on the course of diseases is considered.

Key words: nervous diseases, autoimmune diseases, treatment, extracorporeal photochemotherapy.

(For citation: Borodin A.V. Transimmunization method in the treatment of multiple sclerosis. Practical Medicine. 2018)

REFERENCES

1. Hitzen R., Polman C.H., Lucas C.J., van Lier R.A. Multiple sclerosis: immunological findings and possible implications for therapy. Neuroimmunol, 1992, vol. 39, pp. 1-10.
2. Martin R., Clabresi P., Mc Farland H.F. Experimental immunotherapies of multiple sclerosis. In Zhang J., Hafler D., Hohfeld R., Miller A., eds. London: Martin Dunitz, 1998. Pp. 29-73.
3. Budde H., Berntsch U., Riggert J., Legler T.J. In vitro effects of different 8-methoxypsoralen treatment protocols for extracorporeal photopheresis on mononuclear cells. Eur. J. Immunol, 2017, vol. 42, no. 1, pp. 1-9.
4. Edelson R.L. Extracorporeal photopheresis. Am. Soc. Artif. Intern. Organs, 1984, vol. 30, pp. 674-5.
5. Edelson R.L., Berger C.L., Gasparro F.P. et al. Treatment of leukemic cutaneous T-cell lymphoma with extracorporeally photoactivated 8-methoxypsoralen. Engl. J. Med, 1987, vol. 316, pp. 297-303.
6. Alfred A., Taylor P.C., Dignan F. et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. J. Haematol, 2017, vol. 177, no. 2, pp. 287-310.
7. Sanyal S., Child F., Alfred A. et al. K. national audit of extracorporeal photopheresis in cutaneous T-cell lymphoma. Br. J. Dermatol., 2018, vol. 178, no. 2, pp. 569-570.
8. Pretagostini R., Poli L., Gozzer M. et al. Plasmapheresis, Photopheresis, and Endovenous Immunoglobulin in Acute Antibody-mediated Rejection in Kidney Transplantation. Transplant Proc, 2015, vol. 47, no. 7, pp. 2142-4.
9. Moniodis A., Townsend K., Rabin A. et al. Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction. Heart Lung Transplant, 2017, vol. 36, no. 10, pp. 1070-1079.
10. Liszewski W., Omland S.H., Gniadecki R. The successful use of extracorporeal photopheresis in a 12-year-old patient with refractory epidermolysis bullosa acquisita. Dermatol., 2015, vol. 32, no. 2, pp. 60-1.
11. Molochkov A.V., Kil’dyushevskiy A.V., Karzanov O.V., Bagapsh L.S. Clinical efficacy of extracorporeal photochemotherapy for lupus erythematosus. Al’manakh klinicheskoy meditsiny, 2014, 34, pp. 15-19 (in Russ.).
12. Fotoferez v dermatovenerologii, pod red. Molochkova V.A., Kil’dyushevskogo A.V., Molochkova A.V. [Photopheresis in dermatovenereology, ed. Molochkov V.A., Kildyushevskiy A.V., Molochkov A.V.]. Binom, 2014. 152 p.
13. Atilla E., Atilla P.A., Bozdag S.C. et al. Extracorporeal photochemotherapy in mycosis fungoides. Transfus Clin. Biol, 2017, vol. 24, no. 4, pp. 454-457.
14. Hanel W., Briski R., Ross C.W. et al. A retrospective comparative outcome analysis following systemic therapy in Mycosis fungoides and Sezary syndrome. Am. J. Hematol, 2016, vol. 91, no. 12, pp. 491-495.
15. Kuzmina Z., Stroncek D., Pavletic S.Z. Extracorporeal photopheresis as a therapy for autoimmune diseases. J. Clin. Apher, 2015, vol. 30, no. 4, pp. 224-37.
16. Visser O., Schoordijk M.C. Extracorporeal photopheresis, the Dutch experience. Transfus Apher Sci, 2013, vol. 48, no. 2, p. 167.
17. Comi G. Extracorporeal phototherapy in multiple sclerosis. Neurol Sci, 2006, apr. 27 (1), pp. 3-4.
18. Neretin V.Ya., Kil’dyushevskiy A.V., Agafonov B.V. et al. Photopheresis a new method of treating myasthenia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2003, vol. 103, no. 6, pp. 11-14 (in Russ.).
19. Lolli F., Liuz G.M., Wergelli M. et al. Antibodies specific for the lipid-bound form of myelin basic protein during experimental autoimmune encephalomyelitis. J. Neuroimmunol, 1993, vol. 44, pp. 69-75.
20. Cavaletti G., Perseghin P., Dassi M. et al. Extracorporeal photochemopherapy reduces the incidence of relapses in experimental allergic encephalomyelitis in DA rats. J. Neurol, 2001, 248, pp. 535-6.
21. Cavaletti G., Perseghin P., Buscemi F. et al. Immunomodulationg effects of extracorporeal photochemotherapy (ECP) in rats experimental allergic encephalomyelitis (EAE). Int. J. Tissue React, 2001, vol. 23, pp. 21-31.
22. Cavaletti G., Perseghin P., Dassi M. et al. Extracorporeal photochemotherapy reduces the severity of Lewis rat experimental allergic encephalomyelitis through a modulation of the function of peripheral blood mononuclear cells. J. of Biological Regulation and Homeostatic Agents, 2004, vol. 18, no. 1, pp. 9-17.
23. Cavaletti G., Perseghin P., Dassi M. et al. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis. Neurol. Sci, 2006, Apr, 27 (1), pp. 24-32.
24. Poehlau D., Rieks M., Postert T. et al. Photopheres is a possible treatment of multiple sclerosis: report of two cases. J Clin Apher. 1997;12(3):154-5.
25. Rostami A.M., Sater R.A., Bird S.J. et al. A double-blind, placebo-controlled trial of extracorporeal photopheresis in chronic progressive multiple sclerosis. Mult Scler, 1999 Jun, 5 (3), pp. 198-203.
26. Besnier D.P., Chabannes D., Mussini J.M. et al. Extracorporeal photochemotherapy for secondary chronic progressive multiple sclerosis: a pilot study. Photodermatol. Photoimmunol. Photomed, 2002, vol. 18, no.1, pp. 36-41.
27. Neretin V.Ya., Kil’dyushevskiy A.V., Lzerova I.V., Golenkov F.K. Sposob lecheniya autoimmunnykh zabolevaniy. Patent na izobretenie RF no. 2159635 ot 27.11.2000 [A method for the treatment of autoimmune diseases. The patent for the invention of the Russian Federation N 2159635 from 11/27/2000].
28. Cervio M., Scudeller L., Viarengo G. et al. Quality control on mononuclear cells collected for extracorporeal photochemotherapy: comparison between two UV-A irradiation devices. Vox Sang, 2015, vol. 109, no. 4, pp. 403-5.